Compliance 14 min read

FDA Detention Without Physical Examination: Removal Guide

J

November 18, 2026

If your shipment has been held at the border and the notice mentions an import alert, you are probably dealing with detention without physical examination, usually shortened to DWPE. It is one of the most frustrating FDA actions for an importer because nothing about the specific shipment in front of you may be wrong. FDA has decided, based on history, that your firm, your product, or your country of origin looks risky enough that the burden shifts to you at every entry.

The biggest mistake companies make is treating each detained shipment as a separate problem. A DWPE listing is a standing condition, and the only real fix is to remove the reason the listing exists and then prove it. This guide walks through how the process works, what causes it, and the practical steps to get off the list.

What Is Detention Without Physical Examination?

Detention without physical examination is an FDA import action in which products from a listed firm, country, or category can be refused admission into the United States without FDA first inspecting or sampling that particular shipment. The legal basis is section 801(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 381(a)), which allows FDA to refuse admission of an article that "appears" to be adulterated, misbranded, or in violation of section 505. The word "appears" matters. FDA does not need a laboratory result on your shipment, only a reasonable basis, which an import alert supplies.

Normally, FDA screens entries, and the agency can examine, sample, or let a shipment proceed. Under DWPE, the entry is detained on the strength of the alert itself. The importer is then expected to overcome the appearance of a violation, typically with evidence such as an accredited laboratory analysis of the shipment.

FDA's Regulatory Procedures Manual, Chapter 9 (Import Operations and Actions), contains the agency's internal guidance on import procedures, including import alerts. Confirm the current chapter title and content on FDA's website before citing it.

What Is an FDA Import Alert?

An import alert is a published notice to FDA field staff that tells them to consider detaining certain products, from certain firms, countries, or regions, because of a pattern of violations or a risk the agency has identified. Most import alerts that cause real pain for importers are DWPE alerts.

Each alert has a number, a title, a reason for the alert, and a guidance section that explains how the agency expects staff to handle entries. The firm and product lists are broken into color-coded sections:

  • Red list: firms or products subject to DWPE. Entries are detained.
  • Yellow list: firms or products that are subject to closer scrutiny, such as sampling, but not automatic detention (used in some alerts only).
  • Green list: firms or products that may be exempt from detention based on evidence submitted to FDA (used in some alerts only).
  • Grey list: firms or products FDA tracks for information or further review; the meaning differs by alert.

The color scheme and the meaning of each list vary by alert, so read the alert you are on and FDA's current import alert guidance rather than assuming. Much of the confusion in this area comes from reading a summary of an import alert and never opening the alert itself.

Two examples of how widely these differ: Import Alert 66-40 addresses drug products from firms that have not met drug CGMP, and Import Alert 99-08 addresses processed human and animal foods for pathogenic contamination. Different products, different evidence, different paths off the list. Confirm the current titles and numbers in FDA's import alert database before you cite them in a response, since FDA revises them.

How Does an Import Alert Differ From a Warning Letter or Form 483?

These get mixed up constantly, so a comparison helps.

Action What it is Binding effect on imports Typical trigger
Form 483 Inspectional observations handed over at close of inspection None by itself Observations during an inspection
Warning Letter Formal notice of significant violations None by itself, but unresolved issues can lead to further action Significant violations, often after a 483
Import alert (DWPE) Standing instruction to detain entries Direct: entries from listed firm or product are detained Inspection findings, sample results, refusal of inspection, or country-level risk
Notice of FDA Action (NOFA) Notice that a specific entry is detained or refused Applies to that entry Import screening or an active alert

A Warning Letter to a foreign firm often precedes an import alert listing, and an unresolved one can be the reason the firm lands on the red list. If you are in that position, the guidance in our breakdown of the difference between a warning letter and a 483 is a useful companion, and the broader warning letter remediation work is often the first half of getting an import alert lifted.

What Causes a Firm or Product to Land on an Import Alert?

There is no single cause, but the triggers fall into a handful of recurring groups.

Inspection findings

A foreign or domestic inspection that finds significant CGMP, HACCP, or preventive controls failures can put a firm on an alert. For drugs, the alert may follow findings tied to 21 CFR Parts 210 and 211. For food, findings under 21 CFR Part 117 or the seafood and juice HACCP rules (21 CFR Parts 123 and 120) are common starting points.

Refusal or delay of inspection

Under section 501(j) of the FD&C Act, a drug is deemed adulterated if the owner or operator delays, denies, or limits an inspection, or refuses to permit entry or inspection. That provision is specific to drugs. For food, section 801(a)(4), added by FSMA section 306, allows refusal of admission when a foreign facility's owner or operator refuses an FDA inspection, and device and other product provisions differ. Firms should not assume a scheduling dispute is only a scheduling dispute, since refused or delayed inspections can support an import alert listing; check the current alert list for the one that applies to your product.

Sample results

Laboratory findings from FDA or state sampling, such as Salmonella in a food, pesticide residues above tolerance, or undeclared ingredients in a supplement, can result in a firm or product being added. A single violative sample sometimes produces a listing, though many alerts require a pattern.

Registration, prior notice, and FSVP failures

Food imports require facility registration (section 415 of the FD&C Act) and prior notice (21 CFR Part 1, Subpart I). Food arriving from an unregistered facility, or without adequate prior notice, is subject to refusal. Importers also have obligations under the Foreign Supplier Verification Programs rule (21 CFR Part 1, Subpart L), and food imported by an importer without an FSVP can be refused admission. For the registration side, our article on FDA registration for foreign manufacturers and US agent requirements covers the groundwork that prevents these refusals.

Country or region-wide issues

Some alerts apply to a whole product category from a geography, often tied to recurring contamination or fraud. If you are in the category, you may be listed or you may be eligible for the green list by demonstrating that you are outside the problem.

Labeling and unapproved drug claims

Products that are misbranded or are unapproved new drugs because of their claims can be detained. Supplements marketed with disease claims are the usual example, and our guide to structure/function versus drug claims is worth a read before you ship.

What Happens When Your Shipment Is Detained?

The sequence is more regimented than it feels in the moment.

  1. Entry and screening. The entry is filed with U.S. Customs and Border Protection and reviewed by FDA.
  2. Notice of FDA Action. FDA issues a notice to the importer or consignee that the entry is detained, usually with a statement of the apparent violation and a reference to the alert.
  3. Opportunity to respond. Under 21 CFR 1.94, the owner or consignee has an opportunity to introduce testimony, orally or in writing, regarding the admissibility of the article. Section 801(a) of the Act provides a reasonable time, set in the notice. FDA notices commonly specify 10 working days from the date of the notice, and extensions may be granted. Check the deadline stated in your notice and treat it as real.
  4. Evidence submission. Under DWPE, this usually means documentation and independent laboratory results showing that the shipment does not have the violation named in the alert.
  5. Decision. FDA, not CBP, decides admissibility: it either releases the entry by issuing a "May Proceed" notification or refuses admission.
  6. If refused. The goods generally must be exported or destroyed under CBP supervision, typically within 90 days of the refusal notice, and CBP, not FDA, can assess liquidated damages against the bond if you do neither.

There is a middle path for some violations. Under section 801(b) and 21 CFR 1.99, an importer can apply for authorization to relabel or otherwise recondition an article so that it complies. That works for a labeling defect and rarely for a contamination problem.

Note that the opportunity to respond to an individual detained entry is different from the process of getting the firm removed from the alert. Winning the first does not end the second.

How Do You Get Removed From an Import Alert?

Here is the practical order of operations. FDA's expectations will differ by alert, so treat this as the skeleton and then check the "Guidance" section of your specific alert for the removal criteria.

Step 1: Read the alert and identify the exact reason

Pull the alert from FDA's database and find the paragraph on the reason for the alert and the section describing how a firm may be removed. Note whether removal depends on inspection, on consecutive entries with passing analyses, on a corrective action package, or on some combination. Also confirm which product codes and which of your facilities are named, because firms are sometimes listed for one product line and then assume everything is blocked.

Step 2: Find the root cause, not the symptom

If the listing followed an inspection, your root cause analysis should tie back to the specific observations or violations. If it followed a sample, you need to explain how the contaminant or residue got in, such as supplier practices, sanitation failures, a cross-contamination route, or an ingredient substitution. A laboratory result showing your next shipment is clean does not explain how the last one became contaminated.

Step 3: Implement and document corrective and preventive actions

For regulated manufacturers, this is where the quality system does the work: CAPA records, revised procedures, retraining records, supplier qualification changes, and validation or verification data. For food facilities, the preventive controls and supply-chain program documentation under 21 CFR Part 117 are the typical anchor. Evidence should be dated, signed, and traceable to the root cause. FDA reviewers read a lot of narrative summaries that point to nothing.

Step 4: Generate objective evidence

What FDA accepts is defined in the guidance section of your specific alert, so start there. Typically this means analytical data from an independent laboratory with documented method validation or accreditation, on product, environmental, or ingredient samples, plus records showing that the corrected process works over time. Many alerts specify a number of consecutive non-violative shipments or samples before removal is considered; that number differs by alert, so take it from the alert text rather than from a general rule.

Step 5: Prepare the removal petition

A removal request is typically submitted to the FDA division or office named in the alert's contact section, which is often the relevant import operations or compliance office. A strong package includes:

  • A cover letter that identifies the firm, FEI number, the alert number, and the product codes involved
  • A short statement of the reason the firm was listed, in FDA's terms rather than yours
  • A root cause analysis
  • A description and evidence of each corrective action
  • Laboratory data, with chain of custody and method information
  • Any third-party audit or inspection reports
  • A named contact with the authority to commit the firm

Keep it organized and easy to check. Reviewers can check a package more easily when each claim in the letter points to a numbered exhibit.

Step 6: Expect questions, and possibly an inspection

For alerts tied to CGMP or similar failures, FDA often wants to confirm the correction by reinspection before removing a firm. That can take time, particularly for foreign sites. Plan for that, and for the cost of continuing to hold inventory or reroute shipments in the meantime.

Step 7: Confirm the update and watch for relisting

When FDA removes a firm, or moves it to the green list, confirm the change appears in the database and tell your customs broker. Relisting is also possible if the problem returns, so the underlying controls need to stay in place after the immediate crisis passes.

What Should You Do Right After a Detention?

The first days set the tone for the rest, and a short checklist keeps people from improvising.

  • Obtain the Notice of FDA Action and note the response deadline under 21 CFR 1.94.
  • Identify the import alert number and read the whole alert.
  • Place a hold on any other in-transit shipments from the same firm or product line.
  • Alert your customs broker and confirm who is receiving FDA correspondence.
  • Gather the paperwork for the entry: invoices, certificates of analysis, supplier records, and FSVP files if applicable.
  • Decide early whether the shipment is worth fighting or should be re-exported. Weigh the value of the goods and your ability to document that this shipment is compliant against storage, demurrage, and testing costs; if the alert names a violation you cannot disprove, re-export or destruction is often the cheaper route.
  • Start the root cause investigation immediately, even before you know whether the detention will stick.

If you are heading toward a larger enforcement problem, the FDA compliance planning and inspection readiness work you do now will affect how the removal request is received later.

Common Mistakes That Prolong DWPE Listings

Some patterns appear again and again.

Submitting data without a cause. A pile of passing lab reports without an explanation of what went wrong invites more questions.

Using the wrong laboratory. Results from a lab that cannot show method validation or accreditation carry little weight with the agency.

Treating the broker as the owner of the problem. Brokers file and communicate, but the regulatory response belongs to the importer and the manufacturer.

Ignoring the alert's own text. Petitions sometimes answer a question the alert never asked.

Letting the response window in the notice lapse. An extension is possible, but it is a request and not an entitlement.

Shipping again too soon. Each new violative entry can prolong the listing, so do not test the system with product you are not confident in.

How Long Does Removal Take?

There is no guaranteed timeline, and FDA does not publish a service standard for removal petitions. The duration depends on the alert type, whether reinspection is needed, how complete your package is, and how many rounds of questions follow. Firms that need a foreign reinspection tend to wait longest. The best predictor of a short timeline is likely a first submission that already answers the questions the reviewer would otherwise send back.

Final Thought

A DWPE listing feels like a customs problem, but it is really a quality-system problem with a customs symptom. The firms that come off the list quickly are usually the ones that stopped arguing about the last shipment and started proving the next hundred will be different. What would FDA need to see, in writing, to believe your process has actually changed?

Before submitting a removal request, have a regulatory professional or counsel familiar with import operations review it.

Last updated: 2026-11-18

Frequently Asked Questions

What does FDA detention without physical examination mean?

It means FDA can detain products from a listed firm, product, or country at the border without first examining or sampling that specific shipment. The authority comes from section 801(a) of the FD&C Act (21 U.S.C. 381(a)), which lets FDA refuse admission of articles that appear to be adulterated, misbranded, or in violation of section 505.

How long do I have to respond to a Notice of FDA Action?

Under 21 CFR 1.94, the owner or consignee has an opportunity to introduce testimony on admissibility within 10 working days of the notice. FDA may grant extensions, but you should request one in writing rather than assume it.

What are the red, yellow, and green lists on an import alert?

The red list covers firms or products subject to detention without physical examination. The yellow list, used in some alerts, covers those subject to closer scrutiny such as sampling. The green list covers firms or products shown not to be subject to detention or exempt from the alert. The structure varies by alert, so read the specific alert.

How do I get removed from an FDA import alert?

Read the alert's removal criteria, identify the root cause, implement and document corrective actions, collect objective evidence such as accredited laboratory results, and submit a removal petition to the FDA office named in the alert. Some alerts require a set number of consecutive non-violative entries or a reinspection before removal.

Can I relabel or recondition a detained shipment instead of destroying it?

Sometimes. Section 801(b) of the FD&C Act and 21 CFR 1.99 allow an importer to apply for authorization to relabel or recondition an article so it complies. This generally fits labeling defects better than contamination or CGMP problems.

J

Jared Clark

Principal Consultant, Certify Consulting

Jared Clark is the founder of Certify Consulting, helping organizations achieve and maintain compliance with international standards and regulatory requirements.

Need Help Now? Don't Wait for the Blog.

If you're facing an FDA inspection, responding to a warning letter, or navigating a regulatory submission — schedule a free consultation with Jared Clark. Expert guidance, no obligation.